The Liver Meeting 2019-Phenotyping NAFLD: Risk Stratification and Managing Co-Morbidities*

Phenotyping NAFLD: Risk Stratification and Managing Co-Morbidities*

Video Transcription

Video Summary

Dr. X discussed managing comorbidities and risk stratification in patients with NAFLD and NASH. Key points included identifying high-risk patients based on fibrosis score, age, diabetes, and smoking status. Advanced fibrosis was a major predictor of mortality and liver transplantation. Factors such as diabetes, obesity, sarcopenia, and alcohol intake were also highlighted. Recommendations for reducing morbidity included weight loss, exercise, avoiding alcohol, and smoking cessation. Screening for HCC was emphasized, with difficulties due to obesity affecting image quality. The importance of statins in reducing portal pressure, selecting specific types of statins for benefits, and other treatments like antihypertensives, hypoglycemics, and supplements were discussed. Lastly, the significance of dietary choices, including coffee and fiber, was emphasized while cautioning against artificial sweeteners.

Asset Caption

Presenter: Kymberly Watt

Keywords

NAFLD

NASH

comorbidities

risk stratification

fibrosis score

liver transplantation